GO:1905899 regulation of smooth muscle tissue development: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905899 (regulation of smooth muscle tissue development) is a biological process term that describes any process that modulates the frequency, rate or extent of smooth muscle tissue development.
• Smooth muscle tissue development is controlled by a network of transcription factors, signaling pathways, and epigenetic regulators that together determine contractile phenotype and tissue architecture [2, 6, 8].
• Key molecular regulators include serum response factor (SRF), myocardin (MYOCD), and Kruppel-like factors, which drive contractile gene expression and maintain the differentiated state [2, 8].
• Dysregulation of smooth muscle tissue development contributes to atherosclerosis, hypertension, and other vascular diseases, where smooth muscle cells switch to synthetic, proliferative phenotypes [3, 4, 7].
• Epigenetic mechanisms, including DNA methylation and histone modification, are emerging as critical regulators of smooth muscle cell plasticity during development and disease.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of genes that regulate smooth muscle tissue development and are essential for target validation [2, 6].
Description
Smooth muscle tissue is a fundamental component of hollow organs, blood vessels, and the respiratory, gastrointestinal, and urogenital tracts. Its development is a tightly regulated process that requires the coordinated activation of contractile gene programs, the repression of synthetic phenotypes, and precise spatial and temporal control of cell proliferation and differentiation [2, 8]. The Gene Ontology (GO) term GO:1905899, regulation of smooth muscle tissue development, captures any process that modulates the frequency, rate or extent of this developmental program. Understanding this term is essential for researchers studying vascular biology, organogenesis, and diseases characterized by aberrant smooth muscle remodeling. Research over the past decades has identified a core set of transcription factors, signaling pathways, and epigenetic modifiers that regulate smooth muscle tissue development. For example, the serum response factor (SRF) and its coactivator myocardin (MYOCD) are master regulators of the contractile smooth muscle phenotype, while Kruppel-like factors and forkhead box proteins modulate phenotypic switching in response to environmental cues [2, 8]. In addition, extracellular matrix components, mechanical forces, and intercellular communication via growth factors such as TGF-beta and PDGF influence smooth muscle cell fate decisions [3, 7]. Dysregulation of smooth muscle tissue development is a hallmark of numerous human pathologies, including atherosclerosis, hypertension, asthma, and intestinal motility disorders. In atherosclerosis, smooth muscle cells undergo transdifferentiation and lipid accumulation, contributing to plaque formation and instability. Similarly, alternative splicing and metabolic reprogramming regulate vascular smooth muscle cell plasticity in vivo. Thus, dissecting the regulatory mechanisms of smooth muscle tissue development is not only a fundamental biological question but also a prerequisite for developing targeted therapies.
regulation of smooth muscle tissue development At A Glance
| GO ID | GO:1905899 |
|---|---|
| GO term | regulation of smooth muscle tissue development |
| Ontology | biological_process |
| Synonym | None |
| Major function | Modulates the frequency, rate or extent of smooth muscle tissue development |
| Related processes | Smooth muscle cell differentiation, proliferation, migration, and contractile phenotype regulation |
| Key regulators | SRF, MYOCD, KLF4, KLF5, TGF-beta signaling, PDGF signaling, epigenetic modifiers |
| Disease relevance | Atherosclerosis, hypertension, asthma, intestinal motility disorders |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, ChIP-seq, imaging |
What Is GO:1905899?
GO:1905899, regulation of smooth muscle tissue development, is defined as any process that modulates the frequency, rate or extent of smooth muscle tissue development. This term encompasses molecular, cellular, and systemic mechanisms that control the initiation, progression, and maintenance of smooth muscle tissue formation. It includes the regulation of smooth muscle cell proliferation, migration, differentiation, and maturation, as well as the assembly of contractile apparatus and extracellular matrix. The term is a biological process and does not have synonyms in the QuickGO database.
Why Is regulation of smooth muscle tissue development Important in Cell Biology?
Regulation of smooth muscle tissue development is critical for normal organ function and for understanding the pathogenesis of prevalent human diseases. Smooth muscle cells are the primary contractile cells in blood vessels, airways, and the gastrointestinal tract, and their proper development ensures adequate blood flow, airway tone, and peristalsis [2, 8]. When this regulation is disrupted, smooth muscle cells can switch from a contractile to a synthetic, proliferative phenotype, a process implicated in atherosclerosis, restenosis after angioplasty, and hypertension [3, 7]. Moreover, epigenetic and splicing regulators have emerged as key modulators of smooth muscle cell plasticity, offering new therapeutic targets [4, 6]. Therefore, studying GO:1905899 provides mechanistic insights into both development and disease, and supports the development of novel interventions.
• Smooth muscle tissue development is essential for the structural and functional integrity of blood vessels, airways, and hollow organs [2, 8].
• Dysregulation of smooth muscle development contributes to atherosclerosis, where smooth muscle cells transdifferentiate and accumulate lipids.
• Alternative splicing and metabolic reprogramming regulate vascular smooth muscle cell plasticity in vivo, influencing disease progression.
• Epigenetic regulation of vascular smooth muscle cells during development and disease is a rapidly growing area with therapeutic potential.
• Arterial smooth muscle dynamics are critical for vascular repair and remodeling after injury.
• Understanding the molecular regulation of contractile smooth muscle phenotype has direct implications for vascular tissue engineering.
• Smooth muscle cell phenotypic switching is a key event in hypertension and restenosis.
• CRISPR-based gene editing enables precise interrogation of regulatory genes in smooth muscle development [2, 6].
• Animal models and cell-based assays are essential for translating findings to human disease.
• Targeting regulators of smooth muscle development may lead to new therapies for cardiovascular and respiratory diseases [3, 6].
What Happens During regulation of smooth muscle tissue development?
Initiation of Smooth Muscle Cell Differentiation
In simple terms: This is the starting point where precursor cells begin to turn into smooth muscle cells.
Smooth muscle tissue development begins with the commitment of mesenchymal or neural crest-derived progenitors to the smooth muscle lineage. This process is driven by the activation of a core transcriptional program that includes serum response factor (SRF) and its coactivator myocardin (MYOCD), which together induce the expression of contractile genes such as ACTA2, MYH11, and CNN1 [2, 8]. Signaling pathways, including TGF-beta and Notch, also contribute to the initiation of differentiation by modulating transcription factor activity. Epigenetic changes, such as DNA demethylation and histone acetylation, facilitate the accessibility of contractile gene promoters.
Proliferation and Migration of Smooth Muscle Cells
In simple terms: Smooth muscle cells multiply and move to form the tissue structure.
During development, smooth muscle cells undergo controlled proliferation and migration to populate developing organs and blood vessels. Growth factors such as PDGF and FGF promote proliferation, while extracellular matrix components and mechanical forces guide migration [2, 7]. The balance between proliferation and differentiation is tightly regulated; excessive proliferation can lead to hyperplasia, whereas premature differentiation can impair tissue growth. Key regulators include Kruppel-like factors (KLF4, KLF5) and forkhead box proteins, which integrate environmental cues.
Assembly of Contractile Apparatus
In simple terms: The cell builds the machinery that allows it to contract.
As smooth muscle cells mature, they assemble a contractile apparatus composed of alpha-smooth muscle actin (ACTA2), smooth muscle myosin heavy chain (MYH11), calponin (CNN1), and smoothelin. This assembly is regulated by SRF-MYOCD-dependent transcription and is influenced by mechanical stretch and extracellular matrix stiffness [2, 5]. The contractile phenotype is maintained by a positive feedback loop involving myocardin and its downstream targets. Disruption of this assembly leads to impaired contractility and is associated with vascular diseases.
Phenotypic Modulation and Plasticity
In simple terms: Smooth muscle cells can change their behavior in response to injury or disease.
Smooth muscle cells are not terminally differentiated; they retain the ability to switch between contractile and synthetic phenotypes. This plasticity is regulated by transcription factors such as KLF4, which represses contractile genes, and by epigenetic modifiers [6, 8]. In response to injury, smooth muscle cells can downregulate contractile markers, proliferate, and migrate, contributing to neointima formation. Alternative splicing of pyruvate kinase muscle (PKM) by PTBP1, regulated by LKB1, has been shown to govern vascular smooth muscle cell plasticity in vivo. Cellular communication network factor 2 (CCN2) also regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis.
Integration with Tissue Architecture
In simple terms: Smooth muscle cells organize with other cells to form functional tissues.
Smooth muscle tissue development is not cell-autonomous; it requires interactions with endothelial cells, fibroblasts, and extracellular matrix. For example, fibroblast lineages in the skin determine dermal architecture, and similar principles apply to smooth muscle-rich tissues. Arterial smooth muscle dynamics are influenced by hemodynamic forces and paracrine signals from endothelial cells. The integration of smooth muscle cells into tissue architecture ensures proper organ function and is essential for vascular integrity.
Key Genes Involved in GO:1905899 regulation of smooth muscle tissue development
The following genes and proteins are key regulators of smooth muscle tissue development, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SRF | Master transcription factor for contractile gene expression | Central regulator of smooth muscle differentiation; target for knockout and overexpression studies [2, 8] |
| MYOCD | Coactivator of SRF; drives contractile phenotype | Key determinant of smooth muscle lineage; studied via knock-in and knockout [2, 8] |
| ACTA2 | Alpha-smooth muscle actin; contractile apparatus component | Marker of differentiated smooth muscle; mutations linked to vascular disease [2, 5] |
| MYH11 | Smooth muscle myosin heavy chain; contractile protein | Essential for contractility; regulated by SRF-MYOCD [2, 5] |
| CNN1 | Calponin; actin-binding protein | Modulates contractility; marker of mature smooth muscle |
| KLF4 | Kruppel-like factor 4; represses contractile genes | Promotes synthetic phenotype; knockout models show enhanced contractility |
| KLF5 | Kruppel-like factor 5; regulates proliferation | Involved in vascular remodeling; studied in knockout mice |
| PTBP1 | RNA-binding protein; regulates alternative splicing | Controls PKM splicing and smooth muscle plasticity |
| LKB1 | Serine/threonine kinase; regulates PTBP1 | Governs vascular smooth muscle cell plasticity in vivo |
| CCN2 | Cellular communication network factor 2 | Regulates transdifferentiation and lipid accumulation in atherosclerosis |
| TGFB1 | Transforming growth factor beta 1 | Promotes contractile phenotype; signaling studied in vitro and in vivo |
| PDGFB | Platelet-derived growth factor beta | Stimulates proliferation and migration; involved in phenotypic switching |
| NOTCH1 | Notch receptor 1 | Regulates smooth muscle differentiation during development |
| ELN | Elastin; extracellular matrix protein | Provides elasticity to arteries; mutations cause supravalvular aortic stenosis |
| COL1A1 | Collagen type I alpha 1 | Major ECM component; influences smooth muscle cell behavior |
| FN1 | Fibronectin 1 | ECM protein; modulates smooth muscle cell adhesion and migration |
| MMP2 | Matrix metalloproteinase 2 | Degrades ECM; involved in vascular remodeling |
| MYH9 | Non-muscle myosin heavy chain 9 | Contributes to contractility and cytoskeletal dynamics |
How Is regulation of smooth muscle tissue development Regulated?
Regulation of smooth muscle tissue development is orchestrated by a complex network of signaling pathways, transcription factors, and epigenetic modifiers. The TGF-beta signaling pathway promotes contractile differentiation through SMAD-mediated activation of SRF and MYOCD. Conversely, PDGF signaling activates KLF4 and other repressors, driving phenotypic modulation. Epigenetic regulation, including DNA methylation and histone acetylation, controls the accessibility of contractile gene promoters and is dynamically altered during development and disease. Additionally, alternative splicing regulators such as PTBP1, under the control of LKB1, modulate metabolic and contractile gene programs. Mechanical forces and extracellular matrix stiffness also feed into this regulatory network, influencing smooth muscle cell fate [2, 7].
regulation of smooth muscle tissue development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCN2 | Atherosclerosis; smooth muscle transdifferentiation and lipid accumulation | Knockout mouse, overexpression in smooth muscle cells |
| PTBP1 | Vascular smooth muscle plasticity; atherosclerosis | Conditional knockout, point mutation |
| LKB1 | Vascular smooth muscle plasticity; atherosclerosis | Knockout, knock-in |
| KLF4 | Hypertension, atherosclerosis; phenotypic modulation | Knockout, overexpression |
| SRF | Vascular development; contractile gene regulation | Knockout, knock-in [2, 8] |
Atherosclerosis
Atherosclerosis is characterized by the accumulation of lipids and fibrous elements in the arterial wall, in which smooth muscle cells play a central role. Dysregulated smooth muscle tissue development contributes to disease progression, as smooth muscle cells switch from a contractile to a synthetic phenotype, migrate into the intima, and contribute to plaque formation [3, 7]. CCN2 has been shown to regulate smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis. Additionally, alternative splicing of PKM by PTBP1, regulated by LKB1, governs vascular smooth muscle cell plasticity and influences atherosclerotic lesion development.
Hypertension and Vascular Remodeling
Hypertension is associated with structural changes in blood vessels, including smooth muscle hypertrophy and hyperplasia. Abnormal regulation of smooth muscle tissue development leads to increased vascular tone and remodeling [2, 8]. KLF5 and other transcription factors have been implicated in these processes, and targeting them may provide therapeutic benefits. Arterial smooth muscle dynamics are critical for repair after injury, and their dysregulation contributes to restenosis.
Asthma and Airway Remodeling
In asthma, airway smooth muscle mass increases due to enhanced proliferation and hypertrophy, contributing to airway hyperresponsiveness. The regulation of smooth muscle tissue development is therefore directly relevant to asthma pathogenesis [2, 8]. Growth factors and inflammatory cytokines modulate smooth muscle cell phenotype, and understanding these mechanisms may lead to new treatments.
Intestinal Motility Disorders
Smooth muscle tissue development is essential for normal gastrointestinal motility. Disruptions in the regulatory networks that control smooth muscle differentiation can lead to motility disorders such as chronic intestinal pseudo-obstruction [2, 8]. Research into the molecular regulation of contractile phenotype has implications for these conditions.
From regulation of smooth muscle tissue development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate smooth muscle differentiation? | CRISPR knockout in primary smooth muscle cells or mouse models |
| Does a specific point mutation in gene X alter contractile function? | Point mutation knock-in via CRISPR |
| Does overexpression of gene X promote contractile phenotype? | Overexpression via lentiviral transduction or transgenic mice |
| Does gene X regulate alternative splicing in smooth muscle? | Knockout of splicing factor, RNA-seq |
| Does epigenetic modification of gene X affect smooth muscle development? | CRISPR-dCas9 epigenetic editing |
| Does gene X influence smooth muscle cell proliferation and migration? | Knockout and scratch assay, proliferation assays |
How to Study the regulation of smooth muscle tissue development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression and splicing | Identify regulators of smooth muscle development |
| ChIP-seq | Transcription factor binding and histone marks | Map regulatory elements in smooth muscle genes [2, 6] |
| CRISPR knockout | Loss-of-function phenotypes | Test causal role of candidate genes |
| CRISPR point mutation | Effect of specific amino acid changes | Model disease-associated mutations |
| CRISPR knock-in | Tagged or reporter gene expression | Track protein localization and dynamics |
| Overexpression | Gain-of-function phenotypes | Assess sufficiency of a gene to drive differentiation |
| Imaging | Cell morphology and contractility | Evaluate smooth muscle cell function |
| Proteomics | Protein abundance and modifications | Identify downstream effectors |
Transcriptomic Analysis (RNA-seq)
RNA sequencing allows comprehensive profiling of gene expression changes during smooth muscle tissue development. It can identify differentially expressed transcription factors, contractile genes, and splicing variants. For example, RNA-seq has been used to study alternative splicing of PKM in vascular smooth muscle cells. This method is essential for understanding the regulatory networks governed by GO:1905899.
Chromatin Immunoprecipitation Sequencing (ChIP-seq)
ChIP-seq identifies genome-wide binding sites of transcription factors and histone modifications. It has been used to map SRF and MYOCD binding to contractile gene promoters, revealing the transcriptional circuitry of smooth muscle differentiation [2, 6]. This method provides insights into the epigenetic regulation of smooth muscle tissue development.
CRISPR-Based Functional Genomics
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of gene function in smooth muscle development. These approaches can be applied in cell lines, primary cells, and animal models to dissect the roles of specific genes [2, 6]. For instance, knockout of CCN2 has been used to study its role in atherosclerosis.
Imaging and Contractility Assays
Live-cell imaging and contractility assays measure smooth muscle cell contraction and cytoskeletal dynamics. These methods are used to assess the functional consequences of genetic perturbations on smooth muscle phenotype. They complement molecular analyses and provide physiological relevance.
How CRISPR Can Be Used to Study GO:1905899 regulation of smooth muscle tissue development
Knockout
CRISPR knockout is used to delete genes that regulate smooth muscle tissue development, enabling loss-of-function studies. For example, knockout of CCN2 in mice has been used to investigate its role in smooth muscle cell transdifferentiation and atherosclerosis. Knockout of SRF or MYOCD would be lethal or severely impair smooth muscle formation, highlighting their essential roles [2, 8].
Point Mutation
Point mutations can be introduced via CRISPR to model disease-associated variants or to dissect functional domains of regulatory proteins. For instance, point mutations in LKB1 have been used to study its regulation of PTBP1 and smooth muscle cell plasticity. This approach is valuable for understanding how specific amino acid changes affect smooth muscle development.
Knock-in
Knock-in strategies allow the insertion of reporter genes, tags, or human disease alleles into the genome. Tagged knock-in of contractile proteins (e.g., ACTA2-GFP) enables live-cell imaging of smooth muscle differentiation. Knock-in of human mutations can model vascular diseases in mice.
Overexpression
Overexpression of regulatory genes can drive or enhance smooth muscle differentiation. For example, overexpression of MYOCD in fibroblasts can induce a smooth muscle-like phenotype. This approach is useful for gain-of-function studies and for generating smooth muscle cells for tissue engineering.
How EDITGENE Supports regulation of smooth muscle tissue development Research
Researchers studying regulation of smooth muscle tissue development-related genes often need to determine whether a candidate gene is causally involved in smooth muscle differentiation, phenotypic modulation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and overexpression, supported by advanced bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for regulation of smooth muscle tissue development research.
Frequently Asked Questions About regulation of smooth muscle tissue development
What is GO:1905899?
GO:1905899 is a Gene Ontology term for regulation of smooth muscle tissue development, defined as any process that modulates the frequency, rate or extent of smooth muscle tissue development.
What genes are involved in regulation of smooth muscle tissue development?
Key genes include SRF, MYOCD, ACTA2, MYH11, CNN1, KLF4, KLF5, PTBP1, LKB1, and CCN2, among others [2, 3, 4, 8].
Why is regulation of smooth muscle tissue development important?
It is essential for normal blood vessel, airway, and gastrointestinal function, and its dysregulation contributes to atherosclerosis, hypertension, and asthma [2, 3, 7].
What diseases are associated with abnormal smooth muscle tissue development?
Atherosclerosis, hypertension, asthma, and intestinal motility disorders are associated with abnormal smooth muscle tissue development [2, 3, 7].
How is smooth muscle tissue development regulated?
It is regulated by transcription factors (e.g., SRF, MYOCD), signaling pathways (TGF-beta, PDGF), epigenetic modifiers, and alternative splicing regulators [2, 4, 6, 7].
What research methods are used to study regulation of smooth muscle tissue development?
Common methods include RNA-seq, ChIP-seq, CRISPR knockout/knock-in, overexpression, imaging, and contractility assays [2, 4, 5, 6].
What is the role of SRF in smooth muscle tissue development?
SRF is a master transcription factor that, together with MYOCD, drives the expression of contractile genes and maintains the differentiated smooth muscle phenotype [2, 8].
How does KLF4 regulate smooth muscle phenotype?
KLF4 represses contractile gene expression and promotes a synthetic, proliferative phenotype, contributing to phenotypic modulation in disease.
Can CRISPR be used to study smooth muscle tissue development?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect gene function in smooth muscle development [2, 6].
What is the role of epigenetic regulation in smooth muscle tissue development?
Epigenetic mechanisms such as DNA methylation and histone modification control the accessibility of contractile gene promoters and regulate smooth muscle cell plasticity during development and disease.
Conclusion
GO:1905899, regulation of smooth muscle tissue development, encompasses a complex network of transcriptional, signaling, and epigenetic mechanisms that control the formation and function of smooth muscle tissues. Dysregulation of this process is central to prevalent human diseases such as atherosclerosis, hypertension, and asthma. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate these regulatory mechanisms and may lead to novel therapeutic strategies.
References
- 1. Driskell RR et al.. 2013. Distinct fibroblast lineages determine dermal architecture in skin development and repair.. Nature 504(7479):277-281 PMID: 24336287
- 2. Beamish JA et al.. 2010. Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.. Tissue Eng Part B Rev 16(5):467-91 PMID: 20334504
- 3. Xu Q et al.. 2024. Cellular communication network factor 2 regulates smooth muscle cell transdifferentiation and lipid accumulation in atherosclerosis.. Cardiovasc Res 120(17):2191-2207 PMID: 39365752
- 4. Cai Z et al.. 2024. Regulation of Ptbp1-controlled alternative splicing of pyruvate kinase muscle by liver kinase B1 governs vascular smooth muscle cell plasticity in vivo.. Cardiovasc Res 120(14):1780-1793 PMID: 39189621
- 5. Horowitz A et al.. 1996. Mechanisms of smooth muscle contraction.. Physiol Rev 76(4):967-1003 PMID: 8874491
- 6. Natali L et al.. 2026. A Comprehensive Review of Epigenetic Regulation of Vascular Smooth Muscle Cells During Development and Disease.. Biomolecules 16(1) PMID: 41594714
- 7. Roostalu U et al.. 2018. Arterial smooth muscle dynamics in development and repair.. Dev Biol 435(2):109-121 PMID: 29397877
- 8. Manabe I et al.. 2003. Regulation of smooth muscle phenotype.. Curr Atheroscler Rep 5(3):214-22 PMID: 12667435
